Skip to main content
OpenTrials
Completed

NCT Number: NCT03615651

Probiotic Effects on the Microbe-brain-gut Interaction and Brain Activity During Stress Tasks in Healthy Subjects

The aim of this study is to determine if and how the "Probiotic Product" affects functional brain responses in healthy subjects during an emotional- and arithmetic stress task, respectively and in terms of microbe-brain-gut interactions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Örebro University, Campus USÖ, Örebro University Hospital

Örebro, 70182, Sweden

About this study

The aim of this study is to determine if and how the "Probiotic Product" affects functional brain responses in healthy subjects during an emotional- and arithmetic stress task, respectively and in terms of microbe-brain-gut interactions.

In this randomized double-blind placebo-controlled study, n=22 healthy subjects will receive the following interventions in a crossover fashion, separated by a 4-week wash-out period: 1) Probiotic Formula, 2) placebo. After baseline assessments, study participants will start with a 4-week intervention with the study product or the placebo, followed by a 4-week wash-out period and a subsequent 4-week intervention period (placebo or study product, respectively). fMRI (functional magnetic resonance imaging) scanning during two validated stress tasks will be performed after each of the intervention periods (week 4 and week 12). At the same time points and in addition on the days before the 1st and 2nd intervention (baseline 1 and 2), saliva, blood and faecal samples will be collected. Questionnaire data will be collected and psychological tests and instruments will be performed. For one week at baseline and during the intervention periods (last week), subjects will wear actigraphs to record their physical activity and help assess sleep quality. At baseline, subjects will undergo a carbon dioxide (CO2) challenge test as well as a food diary to record dietary habits.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: Age: 18-65 years, males/females.
  • Signed informed consent -

Exclusion criteria

  • Concurrent or recent treatment with drugs affecting intestinal function or mood, e.g., antidepressants (< 12 weeks) or antibiotics (< 12 weeks).
  • Concurrent or recent (< 4 weeks) use of nutritional supplements or herb products affecting intestinal function or mood (e.g. aloe vera, St. John´s Wort, fibers, prebiotics and probiotics).
  • Diagnosis of major psychiatric or somatic disease. 4) Abuse of alcohol or drugs. 5) Recent (< 4 weeks) intake of proton pump inhibitors, proton pump inhibitors, PPIs (e.g., omeprazole).
  • Asthma. 7) Cardiovascular diseases. 8) Epilepsy. 9) Renal failure. 10) Cerebral bleeding or history of cerebral bleeding. 11) Allergic to latex. 12) Pregnancy (assessed by urine test) or breastfeeding. 13) Claustrophobia. 14) Smoking or using tobacco including snuff. 15) Inability to maintain exercise routine and dietary pattern during the study.
  • Consumption of more than 6 cups of coffee/caffeine-containing beverages per day.
  • Professional athlete. 18) Dominant left-hand. 19) Medical implant (e.g., pacemaker). 20) Aneurysm clips in the head. 21) Shunts in the head. 22) Grenade-splinter or metal-splinter in the body (e.g., eyes). 23) Metal or electrodes in the body (e.g., temp-catheter, aorta stent, cochlea implant).
  • Comprehensive tooth-implants or prothesis. 25) Operated in the head. 26) Operated in the heart. 27) Swallowed a video-capsule. 28) Non-corrected astigmatism. 29) Regular intake of systemic corticosteroids and anti-inflammatory medication (including NSAIDs) during the last three months.
  • Visual defect without possibility to use lenses during MRI scanning. 31) Known allergy to milk or soy. 32) Any other reason the investigator feels the subject is not suitable for participation in the study.

Treatment and study plan

Probiotic

Dietary Supplement

The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.

Placebo

Other

Placebo intervention.

Primary outcomes

  1. Change in brain response to validated emotional challenge task (EAT) during functional brain imaging

    Time frame: Comparing week 4 and 12

Secondary outcomes

  1. Change in brain response to a cognitive challenge task (MIST) during functional brain imaging

    Time frame: Comparing week 4 and 12

Other outcomes

  1. Change in physical activity assessed by an actigraphy watch (actiwatch)

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Actigraph data regarding physical activity

  2. Change in sleep quality assessed by an actigraphy watch (actiwatch)

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Actigraph data regarding sleep quality

  3. Change in daily stress levels assessed by an actigraphy watch (actiwatch)

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Actigraph data regarding daily stress levels

  4. Autonomous Nervous System (ANS) Activity, Biopac

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    ANS activity is measures during stressful tasks.

  5. Stroop test

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    The Stroop test is performed for stress induction

  6. HADS (Hospital Anxiety and Depression Scale)

    Time frame: Measured weekly, week 1-12

    Hospital Anxiety and Depression Scale, min score 0, max score 3, total score max 42, subscale anxiety max 21, subscale depression max 21

  7. STAI (State and Trait Anxiety Inventory for Adults)

    Time frame: Measured weekly, week 1-12

    State and Trait Anxiety Inventory for Adults

  8. PSS (Perceived Stress Scale)

    Time frame: Measured weekly, week 1-12

    Perceived Stress Scale, min score 0, max score 40

  9. Euro-QoL

    Time frame: Measured weekly, week 1-12

    Euro Qol- Health-related Quality of Life 5Q-5D-5L, min score 0, max score 20, subscale 0-100

  10. Karolinska Sleep Diary (KSD)

    Time frame: Measured daily, week 1-4 and 8-12

    KSD measures sleep quality in the morning

  11. Karolinska Diary of Workload (KDW)

    Time frame: Measured daily, week 1-4 and 8-12

    KDW measures workload daily in the evening

  12. Cortisol levels during fMRI tasks (Saliva)

    Time frame: Comparing week 4 and 12

    Saliva samples are collected during fMRI to assess cortisol levels

  13. Cortisol awakening rhythm (saliva)

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Saliva samples are collected at home (3 days á 5 samples) to assess cortisol levels

  14. Faecal samples

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Faecal samples will be analyzed for quantitative and qualitative microbial composition by 16S rRNA-based next generation sequencing (NGS)

  15. Change in inflammatory markers

    Time frame: Comparing the change in week 0 compared to 4, and 8 compared to 12 (before and in the end of the two intervention periods)

    Blood samples will be collected after each intervention period to assess inflammatory markers using Enzyme-Linked Immunosorbent Assays (ELISA)s

Sponsors and collaborators

Lead sponsor

Örebro University, Sweden

Other

Collaborators

  • Pfizer

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 6, 2018
Registry last updated
Aug 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.